LGALS3BP (Lectin, Galactoside-Binding, Soluble, 3-Binding Protein, also known as Mac-2 BP or 90K) is a highly glycosylated, secreted oligomeric protein that plays a pivotal role in the tumor microenvironment (TME), cell adhesion, and immune evasion. By interacting with Galectin-3 (LGALS3), integrins, and extracellular matrix proteins, LGALS3BP promotes tumor metastasis, angiogenesis, and drug resistance. It has emerged as a high-value target for monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and combination therapies in oncology and chronic inflammatory diseases.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for LGALS3BP drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LGALS3BP Recombinant Protein HEK293 expressed (Native Glycosylation), High Purity (>95%), Endotoxin Controlled, Sequence Verified. Theoretical MW optimized for oligomeric analysis. |
View LGALS3BP Products |
| Gene Delivery | LGALS3BP Promise-ORF / Lentivirus Full-length ORF for stable cell line construction to evaluate cell-surface association and binding kinetics. |
View LGALS3BP Products |
| Benchmark Ab | Anti-LGALS3BP Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences for binding and internalization validation. |
View LGALS3BP Products |
| Validator | LGALS3BP siRNA Set Target-specific siRNA pool for knockdown verification in functional cell-based assays. |
View LGALS3BP Products |
| Related Target A | LGALS3 (Galectin-3) Primary physiological ligand of LGALS3BP; critical for screening inhibitors that disrupt the LGALS3BP-Galectin-3 pro-metastatic axis. |
View LGALS3 Products |
| Related Target B | SIGLEC1 (CD169) Sialic acid-binding Ig-like lectin 1; interacts with LGALS3BP to mediate immune suppression in the tumor microenvironment. |
View SIGLEC1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Maintaining Native Oligomeric State (Decamer/Dodecamers) | HEK293 expression system preserves complex N-glycans and native quaternary structure essential for ligand binding. |
| High Background Binding in ELISA/SPR | Rigorous purity control (>95% by SDS-PAGE) and low endotoxin levels (<1.0 EU/μg) reduce non-specific interactions. |
| Lack of Validated Positive Controls | Sequence-verified clinical benchmark antibodies available as reference standards. |
| Off-Target Screening and Specificity Validation | Homolog and related galectin-binding protein panels strictly verified by mass spectrometry. |
Live LGALS3BP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for LGALS3BP therapeutics is intensifying, with major players shifting focus from traditional mAbs to multi-functional antibody-drug conjugates (ADCs) and bispecific constructs. Because LGALS3BP is highly upregulated in the extracellular matrix and on the surface of various solid tumors, it serves as an elegant homing target. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of the LGALS3BP-Galectin-3 signaling axis to reverse immune suppression and overcome chemotherapy resistance in refractory solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Biotech Innovators, Academic Medical Centers | Breast Cancer, Melanoma, Pancreatic Ductal Adenocarcinoma | Ligand Blocking Assay (Requires high-purity, natively glycosylated LGALS3BP and LGALS3 proteins) |
| Antibody-Drug Conjugate (ADC) | Oncology-focused Biopharma | Refractory Solid Tumors, Non-Small Cell Lung Cancer (NSCLC) | Internalization and Endosomal Release Assays (Requires stable cell lines generated via Lentivirus) |
| Small Molecule Inhibitors | Global Pharmaceutical Corporations | Fibrotic Diseases, Chronic Inflammation | High-Throughput Binding Screening (Requires biotinylated or tag-specific recombinant proteins) |